MedTrace Logo

Volume Increase Versus Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success

NCT05238727 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-02-14

No results posted yet for this study

Summary

To assess the anesthetic success of inferior alveolar nerve block (IANB), intraoperative pain intensity and need for supplemental anesthesia on administration of 1.8ml or 3.6ml 2% mepivacaine IANB, or 1.8ml 2% mepivacaine IANB plus 1.8ml 4% articaine buccal infiltration (BI) in mandibular molars with symptomatic irreversible pulpitis.

Conditions

  • Symptomatic Irreversible Pulpitis

Interventions

DRUG

1.8 ml mepivacaine hydrochloride

1.8 ml mepivacaine IANB

DRUG

3.6 ml mepivacaine hydrochloride

3.6 ml mepivacaine IANB

DRUG

1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI

1.8 ml mepivacaine IANB plus 1.8 ml articaine BI

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2023-03-31
Completion
2023-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238727 on ClinicalTrials.gov